Clinical Trial Search

Primary: Mean Change From Baseline to Day 85 in the Distance Walked During the 6 Minute Walk Test (MWT) Following Treatment With SUN11031 in Participants Having Cachexia…

Primary: Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 4, 8, 16, and 24 — 5.87; 0.02; 7.01; -0.65 Percentage Change of TMV — p=<0.001

Primary: Weight Changes — 2.3; 4.4 kg

Primary: Six Minute Walk Test — 1071.0; 1005.9 feet — p=.02

Primary: Forced Expiratory Volume in the First Second (FEV1) — 54; 54 Percentage predicted — p=0.09

Primary: Frequency of Cachexia According to Modified Fearon Criteria — 173 Participants

Primary: Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients- Nephrotoxicity - Measured by Serum Creatinine…

Primary: Proportion of Subjects With a Positive Change From Baseline to Week 4 in Lean Body Mass — 8; 6; 5; 3 participants

Primary: Effect of Intervention on Quality of Patient Clinician Communication About End-of-Life Care(QOC) Scale — 23.3; 19.2; 34.0; 25.5 units on a scale — p=0.03

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day

Primary: Intervention Feasibility — 9.2; 6.4 Sessions

Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants

Primary: Composite Antidepressant Score Scale (CAD) — 29; 25; 9; 20 Participants

Primary: Flow-Mediated Dilation (FMD) — 3.1; 6.7; 4.7; 6.9 percentage of change in FMD — p=<0.05

Primary: Hospital Readmission — 1.12; 1.7 hospital readmissions

Primary: Safety of Doxycycline, as Measured by the Number of Subjects With Any Treatment-related Adverse Events. — 3; 1 Participants

Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305

Primary: Mean Number of Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations and Emergency Department (ED) Visits Per Patient Within Each Study Arm — 0.72; 1.40…

Primary: Number of Participants With All-cause Hospitalizations, Emergency Department (ED) Visits, Observation Stays, and Deaths — 864; 883 Participants — p=0.33

Primary: Time to All-cause Mortality or Re-hospitalization During the 180 Days Post-randomization. — 54; 55 Days to event — p=<0.1

Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001

Primary: COPD Diagnosis — 39 participants

Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation

Primary: Time Spent in Physical Activity as Measured by Upright Time (Minutes Per Day) Monitored by ActivPal Monitor — 278; 269; 293; 285 minutes per day

Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml

Primary: Phagocytosis of H. Influenzae Concentration — 0.042; 0.042; 0.014; 0.06 relative fluorescence unit — p=0.05

Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants

Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52

Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio